In another Asian prospective study, Maemondo et al reported efficacy results in 31 elderly patients with an age from 75 to 87 years with advanced NSCLC associated to activating EGFR mutations treated in first line by gefitinib [20]. Here, EGFR is linked to non-small cell lung carcinoma.